

Recommendations from York and Scarborough Medicines Commissioning Committee February 2015

Drug name	Indication	Recommendation	Place in therapy	RAG status	Potential full year cost impact
Melatonin formulations	Sleep disturbance in children and adolescents	Approved	As per hospital trust shared care guidelines	Amber	Already in use
Melatonin (Circadin®)	Primary insomnia in adults	Not approved	This reflects the existing position.	Black	-
Melatonin formulations	Insomnia in adults with ADHD (unlicensed)	Not approved		Black	-
Melatonin formulations	Delayed phase sleep syndrome and parasomnia's	Not approved		Black	
Agomelatine (Valdoxan®)	Treatment of major depressive episodes	Approved	Review of existing position. Restricted to treatment of resistant cases, e.g. after 3 other antidepressants have failed, reserved for hospital use only. Requirement for liver function tests to be checked in line with recent MHRA guidance.	Red	Current prescribing Items 30 Cost £1,967.72 Prescribing to be transferred back to secondary care.
Mezolar® brand of fentanyl patch formulations	Management of severe chronic pain	Approved	Approved as another cost effective formulation option (along with Matrifen® and Fencino® – note concern over peanut/soya allergy with Fencino®) where fentanyl patches are indicated	Green	No further additional costs
Sucalfate enemas (unlicensed)	Treatment of late/chronic radiation induced proctitis	Approved	Hospital use only when no other viable treatment options. Requirement for its use is rare.	Red	CCG to pay costs of drug to hospital. Cost predicted of £9384 for both VoY and SRCCGs.
Mepacrine (unlicensed)	Use in rare dermatological	Approved	Hospital use only. For patients who fail to respond to topical treatments or for whom topical therapy is	Red	CCG to pay costs of drug to hospital.

	conditions (DLE, SCLE)		not appropriate. If an antimalarial is indicated, then mepacrine is used where patients cannot take hydroxychloroquine.		Audit in 12 months.
Nuvaring® (ethinylestradiol with etonogestrel) vaginal ring	Contraceptive	Approved	For use where contraceptive pills or patches are not tolerated or not acceptable to the patient.	Amber – specialist initiation	To be monitored. Approx. £1000.
CoaguChek® anticoagulation monitoring strips	Warfarin anticoagulation monitoring	Not approved	This was an appeal. The previous decision was upheld.	Black	-
Insulin U500 (Humulin R)	Insulin	Approved	Following audit of current treatment options, the committee considered that insulin U500 should move from not commissioned (black) to hospital only (red) status to allow some patients who have failed to tolerate the newer alternative (insulin degludec) to remain on insulin U500.	Red	No new costs.

Additional items:

Vale of York CCG medal ranking – Hypnotics

Vale of York CCG medal ranking - Hayfever/allergic rhinitis

NICE Technology Appraisals

None to report for January 2015 applicable to CCGs